Clinical Trial Detail

NCT ID NCT02250937
Title Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Cladribine

Busulfan

Busulfan + Venetoclax

Fludarabine

Age Groups: child adult senior

No variant requirements are available.